Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin.

Abstract

Rimantadine, ribavirin, and 6-mercapto-9-(tetrahydro-2-furyl)purine, administered intraperitoneally every 8 h for 7 days starting minutes after virus challenge, had no effect on survival and mean survival time of BALB/c mice inoculated intracranially with dengue virus type 2. In contrast, intraperitoneal treatment with ribavirin 2',3',5'-triacetate, a lipophilic analog of ribavirin, effected significant increases in both mean survival time and survival rate, suggesting that ribavirin 2',3',5'-triacetate may be superior to rabavirin for treatment of viral diseases of the brain.

• Authors: W C Koff, R D Pratt, J L Elm Jr, C N Venkateshan, S B Halstead
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 24 Issue 1 Pg. 134-6 (Jul 1983) ISSN: 0066-4804 [Print] United States
• PMID: 6684897 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• 6-mercapto-9-(tetrahydro-2-furyl)purine
• Ribonucleosides
• Rimantadine
• ribavirin 2',3',5'-triacetate
• Ribavirin
• Mercaptopurine
• Adamantane

Topics

• Adamantane (analogs & derivatives)
• Animals
• Brain Diseases (drug therapy)
• Dengue (drug therapy)
• Female
• Mercaptopurine (analogs & derivatives, therapeutic use)
• Mice
• Mice, Inbred BALB C
• Ribavirin (analogs & derivatives, therapeutic use)
• Ribonucleosides (therapeutic use)
• Rimantadine (therapeutic use)